Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Screeners

Top Momentum Stocks

Top Quality Stocks

Top Value Stocks

Top Growth Stocks

Comments

Loading...

Lexaria Bioscience Stock News

LEXXWNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$0.2853

-0.08-22.87%

At close: -

$0.3000

0.015.15%

After Hours: Mar 18, 9:16 AM EDT

Lexaria Bioscience (LEXXW) Forecast

News

Earnings Lexaria Bioscience (LEXXW) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest Lexaria Bioscience Stock News | NASDAQ:LEXXW | Benzinga

Get the latest news on Lexaria Bioscience stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Lexaria Bioscience performance

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Wednesday, April 23, 2025

Lexaria Bioscience Issues Glucagon-like Pepti...
Benzinga Newsdesk - 17 hours ago

Thursday, December 19, 2024

Lexaria Bioscience Announces It Has Begun Dos...
Benzinga Newsdesk - Dec 19, 2024, 9:21AM

Monday, December 09, 2024

Lexaria Bioscience Says Liraglutide Processed...
Benzinga Newsdesk - Dec 9, 2024, 9:13AM

Tuesday, November 26, 2024

Lexaria Bioscience Provides Strategic Update;...
Benzinga Newsdesk - Nov 26, 2024, 9:25AM

Tuesday, October 22, 2024

Lexaria Bioscience Announces That It Has Rece...
Benzinga Newsdesk - Oct 22, 2024, 9:28AM

Tuesday, October 01, 2024

Lexaria Appoints Michael Shankman As Chief Fi...
Benzinga Newsdesk - Oct 1, 2024, 9:27AM

Friday, September 27, 2024

Lexaria Receives Independent Review Board App...
Benzinga Newsdesk - Sep 27, 2024, 9:24AM

Thursday, August 29, 2024

Lexaria Bioscience Announces Tolerability And...
Benzinga Newsdesk - Aug 29, 2024, 9:36AM

Tuesday, July 16, 2024

Lexaria Preparing For Strategic Growth, Expan...
Benzinga Newsdesk - Jul 16, 2024, 9:30AM

Monday, July 08, 2024

Lexaria Receives 3 New Patents For Antiviral ...
Benzinga Newsdesk - Jul 8, 2024, 9:20AM

Thursday, May 23, 2024

Lexaria Awards Contract To A CRO To Perform T...
Benzinga Newsdesk - May 23, 2024, 10:56AM

Monday, May 06, 2024

Lexaria Announces New Research Program To Eva...
Benzinga Newsdesk - May 6, 2024, 9:08AM

Tuesday, April 30, 2024

Lexaria To Receive $4.7M Gross Proceeds In Wa...
Benzinga Newsdesk - Apr 30, 2024, 3:53PM

Tuesday, April 16, 2024

Lexaria Receives Ethics Review Board Approval...
Benzinga Newsdesk - Apr 16, 2024, 9:17AM

Thursday, March 14, 2024

Lexaria Appoints Nelson Cabatuan As Chief Fin...
Benzinga Newsdesk - Mar 14, 2024, 9:22AM

Tuesday, March 05, 2024

Lexaria To Begin Diabetes And Weight Loss Ani...
Benzinga Newsdesk - Mar 5, 2024, 9:10AM

Thursday, December 07, 2023

Lexaria Bioscience Corp. Announces That The C...
Benzinga Newsdesk - Dec 7, 2023, 9:22AM

Friday, October 13, 2023

Lexaria Enters New Global Exclusive Collaboration And License Agreement With SulfoSyn; Global Exclusivity For All Non-Pharmaceutical Applications Of DehydraTECH-Sulforaphane Has Been Awarded
Happy Mohamed - Oct 13, 2023, 9:07AM

Thursday, September 21, 2023

Lexaria To Evaluate Impact Of DehydraTECH On ...
Benzinga Newsdesk - Sep 21, 2023, 9:16AM

Wednesday, August 30, 2023

Lexaria Provides Update On Investigational New Drug Application Progress With The FDA For Its Planned U.S. Phase 1b Hypertension Clinical Trial Designated As HYPER-H23-1
Happy Mohamed - Aug 30, 2023, 9:24AM

Wednesday, August 02, 2023

Lexaria's Plans To Study Weight Loss And Diabetes Control In A Human Clinical Study With DehydraTECH-CBD
Happy Mohamed - Aug 2, 2023, 9:14AM

Friday, July 28, 2023

Lexaria Incorporates New Subsidiary For CPG Products And Updates Human Nicotine Study
Happy Mohamed - Jul 28, 2023, 9:11AM

Wednesday, July 19, 2023

Lexaria Granted Strategically Important New U.S. Patent For DehydraTECH-Nicotine Including Oral Pouch Products
Happy Mohamed - Jul 19, 2023, 9:06AM

Friday, June 16, 2023

Lexaria's DehydraTECH-CBD Lowers Blood Glucos...
Benzinga Newsdesk - Jun 16, 2023, 9:11AM

Tuesday, May 23, 2023

Lexaria's Formulated Cannabidiol Showed Reduction In Pro-Inflammatory Biomarkers Associated with Heart Diseases
Vandana Singh - May 23, 2023, 2:41PM

Thursday, May 18, 2023

Lexaria's Hormone Study Shows Significant Enhancement In Oral Estradiol Delivery
Happy Mohamed - May 18, 2023, 9:08AM

Monday, April 24, 2023

Lexaria Awards CRO Contract For Upcoming U.S. Phase 1b Hypertension Study
Happy Mohamed - Apr 24, 2023, 9:05AM

Thursday, March 02, 2023

Lexaria's DehydraTECH-CBD Diabetes Study Demonstrates Weight Loss, Improved Triglyceride And Cholesterol Levels
Vuk Zdinjak - Mar 2, 2023, 11:13AM

Monday, January 23, 2023

Former President Of GW Pharmaceuticals USA Jo...
Benzinga Newsdesk - Jan 23, 2023, 8:50AM

Wednesday, December 21, 2022

Lexaria's DehydraTECH-CBD Achieves Superior H...
Benzinga Newsdesk - Dec 21, 2022, 9:12AM

Tuesday, December 20, 2022

Lexaria's Human Oral Nicotine Study Begins Do...
Benzinga Newsdesk - Dec 20, 2022, 12:37PM

Tuesday, November 08, 2022

Lexaria Starts Study Evaluating The Effect Of...
Benzinga Newsdesk - Nov 8, 2022, 9:14AM

Thursday, October 27, 2022

Lexaria's Human Clinical HYPER-H21-4 Study
Benzinga Newsdesk - Oct 27, 2022, 9:18AM

Wednesday, July 27, 2022

Lexaria's DehydraTECH CBD Hypertension Study Dosing Complete With No Serious Adverse Events
Vuk Zdinjak - Jul 27, 2022, 11:31AM

Tuesday, July 26, 2022

Lexaria's Licensee Premier Wellness Science C...
Benzinga Newsdesk - Jul 26, 2022, 9:08AM

Tuesday, June 21, 2022

Lexaria Signs Manufacturing And License Agreements With BevNology
Bill Haddad - Jun 21, 2022, 9:11AM

Wednesday, June 08, 2022

Lexaria Grants License To AnodGen Bioceuticals
Bill Haddad - Jun 8, 2022, 9:05AM

Monday, June 06, 2022

Lexaria Files Pre-IND Meeting Request Letter ...
Benzinga Newsdesk - Jun 6, 2022, 9:18AM

Friday, April 22, 2022

Lexaria Bioscience (NASDAQ: LEXX) Secures Patent For DehydraTECH To Deliver Antivirals
InvestorBrandNetwork - Sponsored

Wednesday, April 20, 2022

Lexaria Bioscience (NASDAQ: LEXX) Commences Its Most Comprehensive Study To Date
InvestorBrandNetwork - Sponsored

Tuesday, April 19, 2022

Lexaria Commences Multi-Week Human Clinical H...
Benzinga Newsdesk - Apr 19, 2022, 9:07AM

Wednesday, April 13, 2022

Lexaria Bioscience (NASDAQ: LEXX) Issues Update On Human Nicotine Study
InvestorBrandNetwork - Sponsored

Wednesday, March 16, 2022

Lexaria Bioscience Commences DehydraTECH-CBD Epilepsy Research Program
InvestorBrandNetwork - Sponsored

Tuesday, March 15, 2022

Lexaria Bioscience Reports First Phase Of Its...
Benzinga Newsdesk - Mar 15, 2022, 2:12PM

Tuesday, March 08, 2022

Lexaria Granted Important New Oral Nicotine P...
Benzinga Newsdesk - Mar 8, 2022, 9:16AM

Wednesday, February 02, 2022

Lexaria Highlights Findings In Sildenafil Ani...
Benzinga Newsdesk - Feb 2, 2022, 9:30AM

Wednesday, December 08, 2021

From Benzinga's Global Small Cap Conference: ...
Benzinga Newsdesk - Dec 8, 2021, 9:27AM
Lexaria Issues Follow-U Results From Clinical Study Showing DehydraTECHTM-CBD Reduces Arterial Stiffness
Bill Haddad - Dec 8, 2021, 7:32AM

Wednesday, November 10, 2021

Lexaria 2022 R&D Programs To Include Investig...
Benzinga Newsdesk - Nov 10, 2021, 9:03AM

Wednesday, November 03, 2021

Lexaria Shares Move Higher; Co Announces New ...
Benzinga Newsdesk - Nov 3, 2021, 7:56AM

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Connect With Us

About Benzinga

About Us
Careers
Advertise
Contact Us

Market Resources

Advanced Stock Screener Tools
Options Trading Chain Analysis
Comprehensive Earnings Calendar
Dividend Investor Calendar and Alerts
Economic Calendar and Market Events
IPO Calendar and New Listings
Market Outlook and Analysis
Wall Street Analyst Ratings and Targets

Trading Tools & Education

Benzinga Pro Trading Platform
Options Trading Strategies and News
Stock Market Trading Ideas and Analysis
Technical Analysis Charts and Indicators
Fundamental Analysis and Valuation
Day Trading Guides and Strategies
Live Investors Events
Pre market Stock Analysis and News
Cryptocurrency Market Analysis and News

Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2025 Benzinga | All Rights Reserved